13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001974915
Total reported value
$4.3B
$4.3B
90 檔
21.2%
According to the latest 13F quarterly dataset, Vestal Point Capital, LP managed an equity portfolio of $4.3B at the end of Q1 2026, spanning 90 distinct U.S. exchange-listed positions.
In Q1 2026, Vestal Point Capital, LP displayed an active expansion posture, initiating 37 new positions and adding to 33 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 6.46% | -4.49% | +705.08% | |
| 2 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 5.65% | +2.41% | +19.17% | |
| 3 | ABVX | Abivax Sa-adr | Stock-Other | 4.67% | +2.65% | -21.05% | |
| 4 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 4.60% | +2.80% | — | |
| 5 | ARWR | Arrowhead Pharmaceuticals In | Stock-Healthcare | 3.99% | -0.99% | +152.78% | |
| 6 | ELVN | Enliven Therapeutics Inc | Stock-Other | 3.56% | +1.18% | -15.14% | |
| 7 | RGEN | Repligen CORP | Stock-Healthcare | 3.05% | -1.77% | +1014.46% | |
| 8 | BCAX | Bicara Therapeutics Inc | Stock-Other | 3.02% | +0.62% | +51.75% | |
| 9 | NRIX | Nurix Therapeutics Inc | Stock-Other | 2.82% | +1.74% | +38.59% | |
| 10 | APGE | Apogee Therapeutics Inc | Stock-Other | 2.59% | -2.59% | EXIT | |
| 11 | ASND | Ascendis Pharma A/S | Stock-Other | 2.40% | -2.40% | EXIT | |
| 12 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 2.33% | -0.99% | +372.97% | |
| 13 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 2.25% | +0.84% | +30.91% | |
| 14 | DYN | Dyne Therapeutics Inc | Stock-Other | 2.03% | -0.28% | +3233.33% | |
| 15 | SNY | Sanofi-adr | Stock-Healthcare | 1.89% | +0.10% | — | |
| 16 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 1.87% | +0.07% | +212.22% | |
| 17 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.82% | -1.82% | EXIT | |
| 18 | ✓ | Immatics NV | Stock-Other | 1.70% | -0.24% | +0.82% | |
| 19 | BMY | Bristol-myers Squibb Co | Stock-Healthcare | 1.70% | -0.62% | +300.00% | |
| 20 | ALC | Alcon Inc. | Stock-Healthcare | 1.69% | -0.91% | -27.60% | |
| 21 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 1.66% | +0.94% | +364.96% | |
| 22 | VERA | Vera Therapeutics Inc | Stock-Other | 1.54% | -1.54% | EXIT | |
| 23 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 1.47% | -1.47% | EXIT | |
| 24 | GMED | Globus Medical Inc - A | Stock-Healthcare | 1.47% | +0.10% | -52.12% | |
| 25 | BSX | Boston Scientific CORP | Stock-Healthcare | 1.40% | -1.40% | EXIT | |
| 26 | NUVL | Nuvalent Inc-a | Stock-Other | 1.38% | -1.38% | EXIT | |
| 27 | COGT | Cogent Biosciences Inc | Stock-Other | 1.32% | -1.32% | EXIT | |
| 28 | ANRO | Alto Neuroscience Inc | Stock-Other | 1.30% | -0.82% | -16.94% | |
| 29 | RAPP | Rapport Therapeutics Inc | Stock-Other | 1.26% | -0.55% | +29.39% | |
| 30 | IRON | Disc Medicine Inc | Stock-Other | 1.25% | +1.40% | -4.76% | |
| 31 | UTHR | United Therapeutics CORP | Stock-Healthcare | 1.24% | +4.27% | — | |
| 32 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.09% | -1.09% | EXIT | |
| 33 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.04% | -1.04% | EXIT | |
| 34 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 1.04% | -0.05% | +6.65% | |
| 35 | SLDB | Solid Biosciences Inc | Stock-Other | 1.01% | -0.51% | -14.02% | |
| 36 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.00% | -0.11% | — | |
| 37 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.96% | -0.96% | EXIT | |
| 38 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.95% | -0.95% | EXIT | |
| 39 | REGN | Regeneron Pharmaceuticals | Stock-Healthcare | 0.86% | -0.28% | — | |
| 40 | WAT | Waters CORP | Stock-Healthcare | 0.83% | -0.83% | EXIT | |
| 41 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.83% | -0.21% | — | |
| 42 | INSP | Inspire Medical Systems Inc | Stock-Healthcare | 0.78% | -0.78% | EXIT | |
| 43 | ✓ | Crescent Biopharma Inc. | Stock-Other | 0.77% | -0.08% | — | |
| 44 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.72% | +0.63% | — | |
| 45 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.72% | -0.25% | — | |
| 46 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.68% | -0.68% | EXIT | |
| 47 | BBNX | Beta Bionics Inc | Stock-Other | 0.62% | -0.03% | +268.59% | |
| 48 | NKTR | Nektar Therapeutics | Stock-Other | 0.57% | +1.06% | — | |
| 49 | CYTK | Cytokinetics Inc | Stock-Healthcare | 0.55% | -0.55% | EXIT | |
| 50 | AZN | AstraZeneca PLC | Stock-Healthcare | 0.55% | +1.44% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines Inc | +5.7% | +705.08% | Add |
| 2 | RGEN | Repligen CORP | +2.6% | +1014.46% | Add |
| 3 | ARWR | Arrowhead Pharmaceuticals In | +2% | +152.78% | Add |
| 4 | DYN | Dyne Therapeutics Inc | +2% | +3233.33% | Add |
| 5 | IMCR | Immunocore Holdings Plc-adr | +1.6% | +372.97% | Add |
| 6 | ELVN | Enliven Therapeutics Inc | +1.6% | -15.14% | Trim |
| 7 | BCRX | Biocryst Pharmaceuticals Inc | +1.3% | +212.22% | Add |
| 8 | GLUE | Monte Rosa Therapeutics Inc | +1.3% | +364.96% | Add |
| 9 | BMY | Bristol-myers Squibb Co | +1.2% | +300.00% | Add |
| 10 | NUVL | Nuvalent Inc-a | +1.2% | +947.21% | Add |
| 11 | APGE | Apogee Therapeutics Inc | +1.2% | +100.00% | Add |
| 12 | ASND | Ascendis Pharma A/S | +1.1% | +114.29% | Add |
| 13 | BCAX | Bicara Therapeutics Inc | +1% | +51.75% | Add |
| 14 | SRRK | Scholar Rock Holding CORP | +0.8% | +89.20% | Add |
| 15 | DNLI | Denali Therapeutics Inc | +0.7% | +281.36% | Add |
| 16 | VERA | Vera Therapeutics Inc | +0.6% | +148.76% | Add |
| 17 | ✓ | Crescent Biopharma Inc. | +0.2% | — | Unchanged |
| 18 | OKUR | Onkure Therapeutics Inc-a | +0.2% | +189.74% | Add |
| 19 | XENE | Xenon Pharmaceuticals Inc | +0.1% | +6.65% | Add |
| 20 | AGIO | Agios Pharmaceuticals Inc | +0.1% | +38.46% | Add |
| 21 | RAPP | Rapport Therapeutics Inc | +0.1% | +29.39% | Add |
| 22 | VYGR | Voyager Therapeutics Inc | +0.1% | +103.59% | Add |
| 23 | ✓ | Engene Holdings Inc | +0.1% | +105.21% | Add |
| 24 | SVRA | Savara Inc | +0.1% | +61.90% | Add |
| 25 | TECX | Tectonic Therapeutic Inc | +0.1% | — | Unchanged |
| 26 | ZBH | Zimmer Biomet Holdings Inc | 0% | +26.67% | Add |
| 27 | CLDX | Celldex Therapeutics Inc | 0% | +5.08% | Add |
| 28 | MPLT | Maplight Therapeutics Inc | 0% | +9.09% | Add |
| 29 | RGNX | Regenxbio Inc | 0% | +219.19% | Add |
| 30 | 4XC1 | Kalvista Pharmaceuticals Inc | — | -2.12% | Trim |
| 31 | BBNX | Beta Bionics Inc | — | +268.59% | Add |
| 32 | MGNX | Macrogenics Inc | — | — | Unchanged |
| 33 | TENX | Tenax Therapeutics Inc | — | — | Unchanged |
| 34 | PASG | Passage Bio Inc | -0.1% | — | Unchanged |
| 35 | MYGN | Myriad Genetics Inc | -0.1% | +34.75% | Add |
| 36 | ✓ | Nyxoah S A | -0.1% | -21.53% | Trim |
| 37 | SLDB | Solid Biosciences Inc | -0.1% | -14.02% | Trim |
| 38 | FULC | Fulcrum Therapeutics Inc | -0.1% | +15.79% | Add |
| 39 | NVCR | NovoCure Limited | -0.2% | -52.38% | Trim |
| 40 | NRIX | Nurix Therapeutics Inc | -0.2% | +38.59% | Add |
| 41 | ANRO | Alto Neuroscience Inc | -0.2% | -16.94% | Trim |
| 42 | TSHA | Taysha Gene Therapies Inc | -0.3% | +30.91% | Add |
| 43 | GERN | Geron CORP | -0.4% | -77.56% | Trim |
| 44 | BMRN | Biomarin Pharmaceutical Inc | -0.4% | +19.17% | Add |
| 45 | ✓ | Immatics NV | -0.5% | +0.82% | Add |
| 46 | IRON | Disc Medicine Inc | -0.7% | -4.76% | Trim |
| 47 | LXEO | Lexeo Therapeutics Inc | -0.8% | — | Unchanged |
| 48 | OLMA | Olema Pharmaceuticals Inc | -1.2% | -74.03% | Trim |
| 49 | ALC | Alcon Inc. | -1.3% | -27.60% | Trim |
| 50 | TYRA | Tyra Biosciences Inc | -2.1% | -97.77% | Trim |
According to official SEC Form 13F filings, Vestal Point Capital, LP reported a total U.S. public equity portfolio value of $4.3B across 90 disclosed positions in Q1 2026.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including RVMD, BMRN, ABVX) accounted for 21.2% of total reported equity market value during Q1 2026.
Top New Position Initiated
NBIX
市值: $164.7M
Top Position Liquidated / Trimmed
QQQ
前期市值: $215.0M
During Q1 2026, Vestal Point Capital, LP's top holdings by market value included RVMD (6.5%)、BMRN (5.7%)、ABVX (4.7%). The largest single position, RVMD, represented 6.5% of total portfolio value.
In Q1 2026, Vestal Point Capital, LP made 107 total portfolio adjustments, initiating 37 new buys, adding to 33 positions, trimming 14 holdings, and fully liquidating 23 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.